The World Health Organization (WHO) announced today that GlaxoSmithKline (GSK) will renew its commitment to donate the deworming drug albendazole until the global elimination of lymphatic filariasis as a public health problem. In addition, by 2025, 200 million tablets per year for the treatment of STH will be donated, and by 2025, 5 million tablets per year for the treatment of cystic echinococcosis.
This latest announcement builds on the company's 23-year commitment to combat three Neglected Tropical Diseases (NTDs) that are taking a heavy toll on some of the world's poorest communities.
These commitments are just part of an impressive commitment made by GSK today at the Malaria and Neglected Tropical Diseases Summit in Kigali, where they announced a £1 billion investment over 10 years to accelerate progress on infectious diseases. - countries of income. Press release).
The research will focus on new breakthrough drugs and vaccines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare) and neglected tropical diseases, and address antimicrobial resistance, which continues to affect the most vulnerable populations and cause many deaths. . The burden of disease in many low-income countries exceeds 60%.